US FDA issues warning letter to Granules India's Gagillapur facility

received a Warning Letter from the US FDA for its Gagillapur facility due to regulatory concerns, though operations remain unaffected. The company has addressed most issues and is responding to the FDA. Despite this, Q3 FY25 saw a 6.4% drop in net profit to Rs 118 crore and a 1.5% revenue decline to Rs 1,137.6 crore.